Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor?

@article{Keks2015VortioxetineAM,
  title={Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor?},
  author={Nicholas A Keks and Judith D Hope and Christine Culhane},
  journal={Australasian Psychiatry},
  year={2015},
  volume={23},
  pages={210 - 213}
}
Objective: The treatment of depressive disorders remains unsatisfactory for many patients with regard to efficacy and tolerability. Vortioxetine has been registered by regulatory authorities for the treatment of major depressive disorder. This paper aims to provide clinicians with a brief overview of vortioxetine and its place in treatment. Conclusions: Vortioxetine is a serotonin reuptake inhibitor with additional serotonergic receptor effects of uncertain significance; hence, its… 

Tables from this paper

Current Investigational Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder

The limitations of currently available medications including methylphenidates, amphetamines, atomoxetine, extended- release guanfacine and extended-release clonidine are considered, and drugs in development for the treatment of ADHD are examined.

Inhibitory Effectiveness in Delayed-Rectifier Potassium Current Caused by Vortioxetine, Known to Be a Novel Antidepressant

Overall, inhibitory effects of VOR on ionic currents might constitute another underlying mechanism of its actions.

Drug-Induced Sexual Dysfunction in Individuals with Epilepsy: Beyond Antiepileptic Compounds

Sexual dysfunction (SD) is a multifactorial problem, involving neurological, iatrogenic, endocrine, psychiatric, and psychosocial factors, and affects the quality of life of both male and female

[Role of cAMP/CREB/BDNF signaling pathway in anti-depressive effect of vortioxetine in mice].

Vortioxetine improves the behaviors of mice with depression possibly by affecting the cAMP/CREB/BDNF signal pathway, suggesting the antidepressive effect of against depression in mice.

Vortioxetine in bipolar depression induces a mixed/manic switch

  • C. Maud
  • Psychology
    Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists
  • 2016

References

SHOWING 1-8 OF 8 REFERENCES

Vortioxetine for Major Depressive Disorder

Vortioxetine's multimodal activity can be a useful alternative to other serotonergic antidepressants for some patients who are partial responders or non-responders to other treatment options and appears to have minimal effect on weight and sexual function.

Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials

Therapy with vortioxetine was significantly associated with reduction in depression symptoms from baseline compared to placebo, Nevertheless, a significant number of patients who were on vortoxetine therapy have reported more adverse events.

The US Food and Drug Administration's perspective on the new antidepressant vortioxetine.

The issues that were important to the FDA's approval decision are emphasized, particularly the difference in the effective dose in domestic and foreign studies, and several new labeling features are noted, specifically, description of time course of treatment response and detailed sexual dysfunction evaluation.

Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

  • L. Citrome
  • Psychology
    International journal of clinical practice
  • 2014
The efficacy and safety of vortioxetine for the treatment of major depressive disorder (MDD) are described and the drug is described as safe and effective.

Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

  • L. Citrome
  • Psychology, Biology
    International journal of clinical practice
  • 2013
The efficacy and safety of levomilnacipran (extended‐release capsules) for the treatment of major depressive disorder (MDD) are described.

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†

This randomised, double‐blind, 12‐week study compared efficacy and tolerability of flexible‐dose treatment with vortioxetine (10–20 mg/day) versus agomelatine (25–50 mg/day) in major depressive

Vortioxetine for the Treatment of Depression

Vortioxetine is an effective agent for the treatment of MDD, but it does not have any clear advantages over other available treatment options.